• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Watson Buys Actavis; Stock to Outperform


Watson Pharmaceuticals' purchase of Actavis created the third-largest global generic-drug maker and the company's stock shot up by 5.7%.

On Wednesday, Watson Pharmaceuticals bought Actavis for $5.6 billion, creating the third-largest global generic-drug maker, according to Bloomberg. Watson is the maker of the generic version of Lipitor, and the buyout would give the company a larger presence in Eastern Europe, China and India.

The New Jersey-based company’s stock jumped up to a 52-Week high after the long-rumored buyout was confirmed. Before the deal was announced, Watson’s stock was $69.69 when the markets closed on Wednesday. By early afternoon, the stock price was up 5.7%.

After the deal Morgan Stanley raised the price target for Watson’s stock to $84.

Click to enlarge

The blue triangle in the above graph depicts the range for the stock’s potential price target. The bullish case points the price at $95 in case “revenue and future tax rate synergies yield additional [earnings per share] upside.” The bearish case point the price at $60 if the “acquisition surprisingly fails.”

An analyst at Credit Suisse boosted the price target to $98, according to

Watson anticipates revenue in 2012 to reach $8 billion. The company expects to close the deal by the end of 2012 so that 2013 will be a full year of combined operations.

Click to enlarge


The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.

Read more:

Watson to Buy Actavis for $5.6 Billion in Generics Deal

Analysts Get Hooked on Watson After Actavis Drugs Deal

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice